Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

Notable Labs, Ltd.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.

Notable’s proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product’s medical impact and commercial value faster, higher, and more likely than traditional drug development.

Castor Ventures

11.2 Capital

Alumni Ventures

B Capital

Lifeforce Capital

Industry Ventures

Westwood Ventures

Y Combinator

First Round Capital

Founders Fund

Bioverge

Duro Ventures

Milad Alucozai

Notable

Notable Labs advancing science for MDS and other hematological malignancies. #ash2023

ICYMI: Notable Labs was featured on the front page of the December 10/11, Hematology Daily News distributed at the American Society of Hematology (#ASH23) conference in San Diego. The article, “The Promise of Predictive Medicine is Coming True,” explains how Notable Labs is advancing predictive precision medicine.  According to the article, “Instead of focusing precision medicine on targeting molecular aberrations most likely leading to cancer response, Notable focuses precision on targeting cancer response itself, i.e., on targeting – with precision – the patients most likely to clinically respond to a treatment.” https://lnkd.in/eyfXDhH5

Source Group LLC; Thomas A. Bock, MD, MBA; Chris Leonardi; Joseph Wagner

#hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS

Thomas A. Bock, MD, MBA, Notable Labs, was interviewed by OncologyTube.com during the American Society of Hematology (ASH) Annual Meeting in San Diego, CA.  Dr. Bock discussed Notable’s innovative Predictive Precision Medicine Platform (PPMP) technology platform and the development status of Volasertib, which is being developed for the treatment of acute myeloid leukemia (AML).
 
#ASH23 #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS

Exemplifying the company's strong commitment to research and development of precision treatments for MDS, Notable Labs has donated $60,000 to the Myelodysplastic Syndromes Foundation. The donation was formally announced during the MDS Foundation 2023 Satellite Symposium at the 65th American Society of Hematology (#ash23 ) Annual Meeting which Notable Labs also supported. "Supporting the MDS Foundation directly aligns with our desire to affect positive change for patients affected by this cancer with high unmet need,” said Thomas A. Bock, MD, MBA, CEO, Notable Labs. “Furthermore, the donation helps to fund the dedicated researchers who work tirelessly to find cures for this rare, often undetected disease." https://lnkd.in/ewGqtMug
Tanya Gleeson Rhodes; Stephen Nimer; Chris Leonardi; MDS Foundation, Inc.

#ASH23 #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS

The future of personalized medicine and therapeutic optimization: Notable's Predictive Precision Medicine Platform (PPMP). What is it? How does it work? and Why you'll want to know about it...all at the American Society of Hematology (#ash2023), BOOTH #2454. biomedwoRx: Life Sciences Consulting

#aml #mds #hematology

MEET US AT ASH! Mark your calendar to visit Notable at Booth #2454 at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition December 9-12, 2023, in San Diego, CA. Schedule a meeting to learn about our Predictive Precision Medicine Platform (PPMP) and our lead therapeutic, volasertib, a highly potent PLK1 inhibitor proven to induce cell cycle arrest and apoptosis in various cancer cells. Contact us through LinkedIn message or https://lnkd.in/eAgN3cFt before Monday, Dec 11th for an exclusive event invitation!  
 
#ASH23 #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS

We're #hiring a new Product Development Associate Scientist in San Mateo, California. Apply today or share this post with your network.

We're #hiring a new Product Development Associate Scientist in Foster City, California. Apply today or share this post with your network.

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			13.86M -	585K 95.78%	562K 3.93%	922K 64.06%	285K 69.09%	8K 97.19%	310K 3,775%
cost of revenue	122K -	130K 6.56%	496K 281.54%	1.39M 180.44%	1.44M 3.59%	1.59M 10.20%	1.62M 2.08%	1.16M 28.32%	197K 83.05%
gross profit	-122K -	-130K 6.56%	13.37M 10,383.08%	-806K 106.03%	-879K 9.06%	-666K 24.23%	-1.34M 100.60%	-1.15M 13.62%	113K 109.79%
selling and marketing expenses
general and administrative expenses							5.73M -	5.16M 9.97%	10.06M 95.19%
selling general and administrative expenses	3.64M -	3.79M 4.04%	6.36M 67.96%	5.55M 12.77%	5.71M 2.90%	5.36M 6.18%	5.73M 6.95%	5.16M 9.97%	10.06M 95.19%
research and development expenses	12.96M -	14.06M 8.47%	19.85M 41.21%	16.87M 15.03%	13.49M 20.00%	18.46M 36.81%	11.47M 37.86%	7.78M 32.22%	4.71M 39.48%
other expenses							862K -	-1.48M 272.04%	-1.56M 4.99%
cost and expenses	16.72M -	17.98M 7.49%	26.71M 48.58%	23.81M 10.86%	20.64M 13.29%	25.41M 23.06%	17.20M 32.30%	12.93M 24.81%	14.97M 15.74%
operating expenses	16.60M -	17.84M 7.50%	26.21M 46.89%	22.42M 14.48%	19.20M 14.33%	23.82M 24.03%	17.20M 27.79%	12.93M 24.81%	14.77M 14.21%
interest expense	16K -	12K 25%	27K 125%	37K 37.04%	184K 397.30%	105K 42.93%
ebitda	-16.60M -	-17.84M 7.50%	-12.69M 28.90%	-22.07M 73.91%	-18.86M 14.52%	-23.29M 23.46%	-16.59M 28.77%	-12.60M 24.04%	-19.35M 53.56%
operating income	-16.72M -	-17.98M 7.49%	-12.84M 28.55%	-23.22M 80.80%	-20.08M 13.52%	-24.48M 21.92%	-16.91M 30.92%	-12.92M 23.59%	-14.66M 13.41%
depreciation and amortization	122K -	130K 6.56%	156K 20%	1.16M 641.03%	1.22M 5.45%	1.19M 2.05%	326K 72.70%	323K 0.92%	257K 20.43%
total other income expenses net	1.83M -	1.97M 7.58%	2.71M 37.15%	2.76M 2.14%	686.00K 75.18%	258.00K 62.39%	862K 234.11%	-1.48M 272.04%	3.39M 328.79%
income before tax	-14.89M -	-16.00M 7.48%	-10.14M 36.65%	-20.46M 101.80%	-19.40M 5.19%	-24.23M 24.90%	-16.05M 33.74%	-14.41M 10.25%	-11.26M 21.82%
income tax expense		-1 -		-1 -	-1 0%	-1 0%			-4.95M -
net income	-14.89M -	-16.00M 7.48%	-10.14M 36.65%	-20.46M 101.80%	-19.40M 5.19%	-24.23M 24.90%	-16.05M 33.74%	-14.41M 10.25%	-11.26M 21.82%
weighted average shs out	20.31M -	24.97M 22.95%	27.40M 9.72%	32.97M 20.33%	35.88M 8.83%	43.67M 21.70%	8.94M 79.54%	77.55M 767.85%
weighted average shs out dil	20.31M -	24.97M 22.95%	27.40M 9.72%	32.97M 20.33%	35.88M 8.83%	43.67M 21.70%	8.94M 79.54%	77.55M 767.85%
eps	-0.73 -	-0.64 12.33%	-0.37 42.19%	-0.62 67.57%	-0.54 12.90%	-0.55 1.85%	-1.80 227.27%	-0.19 89.44%
epsdiluted	-0.73 -	-0.64 12.33%	-0.37 42.19%	-0.62 67.57%	-0.54 12.90%	-0.55 1.85%	-1.80 227.27%	-0.19 89.44%

NASDAQ:NTBL

Notable Labs, Inc.

Last Close

0.61

30/08 20:00

Market Cap

5.03M

Beta: -

Volume Today

28.46K

Avg: 96.74K

PE Ratio

−13.63

PFCF: −1.03

Preview